Limits...
HIV co-infection accelerates decay of humoral responses in spontaneous resolvers of HCV infection.

Liu Y, Shen T, Zhang C, Long L, Duan Z, Lu F - J. Viral Hepat. (2014)

Bottom Line: We found that the annual decreasing rate of anti-HCV presented a gradually accelerated process in HCV resolvers.However, the variation in the decline of anti-HCV presented a slowly accelerated process within the early decrease stage and a gradually decelerated process within the latter decrease stage.Our data indicated that the decay of anti-HCV was accelerated by HIV-related impairment of immune function.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, Peking University Health Science Center, Beijing, China; Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Henan, China.

Show MeSH

Related in: MedlinePlus

Predicting overall time for loss of detectable anti-HCV in SR-HCV individuals. (a) The average annual decreasing rate of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding linear regression equations. (b) The deduced decaying time of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding predicted annual decreasing rate of anti-HCV antibodies. A significant difference of the deduced decaying rate (P < 0.001) and time (P < 0.001) of anti-HCV between HIVneg SR-HCV and HIVpos SR-HCV groups was verified by Wilcoxon matched-pairs t-test (P < 0.001). (c) (d) The overall time ranges for the level of anti-HCV in SR-HCV individuals to drop from a detectable level at the point of resolution of the infection to S/CO values equal to one were predicted both for HIV-uninfected population (c) and HIV-infected population (d).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263235&req=5

fig03: Predicting overall time for loss of detectable anti-HCV in SR-HCV individuals. (a) The average annual decreasing rate of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding linear regression equations. (b) The deduced decaying time of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding predicted annual decreasing rate of anti-HCV antibodies. A significant difference of the deduced decaying rate (P < 0.001) and time (P < 0.001) of anti-HCV between HIVneg SR-HCV and HIVpos SR-HCV groups was verified by Wilcoxon matched-pairs t-test (P < 0.001). (c) (d) The overall time ranges for the level of anti-HCV in SR-HCV individuals to drop from a detectable level at the point of resolution of the infection to S/CO values equal to one were predicted both for HIV-uninfected population (c) and HIV-infected population (d).

Mentions: Depending on the linear regression equations ‘y = −0.894x+18.35’ and ‘y = −1.192x+23.35’ shown in Fig. 2a, b, the annual decreasing rate of anti-HCV at different ranges of anti-HCV S/CO values (e.g. 15–14, 14–13, 13–12……) is predicted in Fig. 3a, which clearly shows that the annual decreasing rates of anti-HCV increased gradually over time and HIV co-infection significantly enhanced this decrease in SR-HCV individuals (P < 0.001).


HIV co-infection accelerates decay of humoral responses in spontaneous resolvers of HCV infection.

Liu Y, Shen T, Zhang C, Long L, Duan Z, Lu F - J. Viral Hepat. (2014)

Predicting overall time for loss of detectable anti-HCV in SR-HCV individuals. (a) The average annual decreasing rate of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding linear regression equations. (b) The deduced decaying time of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding predicted annual decreasing rate of anti-HCV antibodies. A significant difference of the deduced decaying rate (P < 0.001) and time (P < 0.001) of anti-HCV between HIVneg SR-HCV and HIVpos SR-HCV groups was verified by Wilcoxon matched-pairs t-test (P < 0.001). (c) (d) The overall time ranges for the level of anti-HCV in SR-HCV individuals to drop from a detectable level at the point of resolution of the infection to S/CO values equal to one were predicted both for HIV-uninfected population (c) and HIV-infected population (d).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263235&req=5

fig03: Predicting overall time for loss of detectable anti-HCV in SR-HCV individuals. (a) The average annual decreasing rate of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding linear regression equations. (b) The deduced decaying time of anti-HCV of HIVneg SR-HCV (●) and HIVpos SR-HCV (○) groups at different ranges of anti-HCV S/CO values was predicted based on the corresponding predicted annual decreasing rate of anti-HCV antibodies. A significant difference of the deduced decaying rate (P < 0.001) and time (P < 0.001) of anti-HCV between HIVneg SR-HCV and HIVpos SR-HCV groups was verified by Wilcoxon matched-pairs t-test (P < 0.001). (c) (d) The overall time ranges for the level of anti-HCV in SR-HCV individuals to drop from a detectable level at the point of resolution of the infection to S/CO values equal to one were predicted both for HIV-uninfected population (c) and HIV-infected population (d).
Mentions: Depending on the linear regression equations ‘y = −0.894x+18.35’ and ‘y = −1.192x+23.35’ shown in Fig. 2a, b, the annual decreasing rate of anti-HCV at different ranges of anti-HCV S/CO values (e.g. 15–14, 14–13, 13–12……) is predicted in Fig. 3a, which clearly shows that the annual decreasing rates of anti-HCV increased gradually over time and HIV co-infection significantly enhanced this decrease in SR-HCV individuals (P < 0.001).

Bottom Line: We found that the annual decreasing rate of anti-HCV presented a gradually accelerated process in HCV resolvers.However, the variation in the decline of anti-HCV presented a slowly accelerated process within the early decrease stage and a gradually decelerated process within the latter decrease stage.Our data indicated that the decay of anti-HCV was accelerated by HIV-related impairment of immune function.

View Article: PubMed Central - PubMed

Affiliation: Department of Microbiology, Peking University Health Science Center, Beijing, China; Department of Nutrition and Food Hygiene, College of Public Health, Zhengzhou University, Henan, China.

Show MeSH
Related in: MedlinePlus